MINNEAPOLIS, MN, US, April 25, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Mary Grace Rutland has accepted a position with the Company as its new Business Development Manager for the Mid-Atlantic Region of the United States.
"We are incredibly excited to add Mary Grace to our sales and distribution team,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “The experience Mary Grace brings to PetVivo is extraordinarily valuable to our efforts in introducing our innovative product Spryng™ with OsteoCushion™ technology to veterinarians throughout the Mid-Atlantic states as well as the entire United States”
Mary Grace Rutland (MG) brings to PetVivo 24 years of animal health sales and management experience. Her love of horses took her to the University of Kentucky where she earned a degree in equine science. During her career, Mary Grace has held positions such as senior equine territory for Fort Dodge Animal Health, veterinary field sales manager for Neogen Corporation, and digital imaging specialist for Cuattro. To further her companion animal industry experience, Mary Grace sold in-house lab analyzers for Heska Corporation and most recently was a practice growth consultant for Antech Diagnostics.
“I am incredibly excited to have the opportunity to join the PetVivo sales and marketing team. It is a pleasure to be part of a team that possesses vast experience in the development and commercialization of life changing veterinary medical devices,” said Ms. Rutland. “I truly believe Spryng with OsteoCushion Technology has the ability to improve the medical outcomes of animals suffering from lameness and other joint related afflictions, such as osteoarthritis, thereby enhancing the lives of animals and their owners.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.
John Lai, CEO
PetVivo Holdings, Inc.
Forward-Looking commercial Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.